Oncology events & webinars
Explicyte presents at and attends oncology conferences, scientific meetings, and webinars worldwide — sharing peer-reviewed spatial biology and immuno-oncology research alongside our partners. Explore where we've been and where to meet us next.
PSCC Summer Science Summit
Represented by Imane Nafia, CSO
Attending this French Immuno-Oncology gathering hosted by the Paris-Saclay Cancer Cluster (PSCC)
Basel Single Cell & Spatial Day
Represented by Alban Bessede, CEO and Jean-Philippe Guegan, CTO
Speaking at the 4th edition of the Basel Single Cell & Spatial Day, co-hosted by 10x Genomics & Novartis.
Kadans Oncology Summit
Represented by Loic Cerf, COO
Spending the day with the French oncology community of the Paris-Saclay Cancer Cluster (PSCC) at the Hive.
ASCO 2026
Represented by Alban Bessede, CEO and Jean-Philippe Guegan, CTO
Prof. Italiano Antoine (Gustave Roussy) will take the stage at the 2026 ASCO Annual Meeting in Chicago to present a spatial atlas of ADC targets in immunotherapy-treated NSCLC (first author: Jean-Philippe Guegan, CTO, Explicyte)
Xenium for drug development: Analyzing cancer survivors, profiling lead compounds
Represented by Alban Bessede, CEO
A webinar hosted by 10x Genomics with Alban Bessède, CEO of Explicyte, and Paloma Cejas, Chief of Biology at Cure51. Presenting an in vitro proof-of-concept using Xenium with the STAMP workflow on PBMCs exposed to cancer immunotherapy.
ASCO annual meeting 2025
Represented by Alban Bessede, CEO
2 posters: "Spatial transcriptomics reveal crucial determinants of immune exclusion in non-small cell lung cancer From the Precision Medicine BIP Study" In collaboration with GSK, Institut Bergonié, and Gustave Roussy + "CCR8⁺ regulatory T cells and their correlation with immunotherapy response in advanced NSCLC In collaboration" with Bayer AG, Institut Bergonié, and Gustave Roussy
AACR Annual Meeting 2022
Represented by Alban Bessede, CEO and Jean-Philippe Guegan, CTO
4 posters presented: Development and characterization of a novel anti-PD1 resistant sarcoma mouse model / High regulatory T cells infiltrate within tertiary lymphoid structure restricts response to immune checkpoint blockers in sarcomas / Low plasma Arginine level is associated with resistance to immune checkpoint inhibitors in patients with advanced cancer / Ovarian cancer ascites display altered immune environment featured by enhanced soluble factors and suppressive cellular context
AACR Virtual Annual Meeting 2020
Represented by Alban Bessede, CEO
Explicyte was pleased to present our posters featuring our capacities / platforms that support drug discovery.
ESMO Immuno-Oncology 2019
Represented by Alban Bessede, CEO
Presentïng the poster “Comprehensive assessment of anti-tumor PDL1 blockade effect in a sarcoma mouse model“
ASCO Annual Meeting 2019
If you attend the ASCO Annual Meeting this year in Chicago, we will be glad to take this opportunity to meet you there and discuss the way Explicyte can support your clinical research programs.
AACR Annual Meeting 2019
Presenting the poster “The Kynurenine Pathway as a possible resistance mechanism to immunotherapy in sarcomas”